CVKD vs. ADIL, YMTX, PTIX, TENX, IBIO, CLVR, TRVN, ENVB, CANF, and SHPH
Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Adial Pharmaceuticals (ADIL), Yumanity Therapeutics (YMTX), Protagenic Therapeutics (PTIX), Tenax Therapeutics (TENX), iBio (IBIO), Clever Leaves (CLVR), Trevena (TRVN), Enveric Biosciences (ENVB), Can-Fite BioPharma (CANF), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.
Adial Pharmaceuticals (NASDAQ:ADIL) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.
Adial Pharmaceuticals received 105 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote.
16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 14.5% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 58.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cadrenal Therapeutics has a consensus price target of $3.50, suggesting a potential upside of 713.01%. Given Adial Pharmaceuticals' higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Adial Pharmaceuticals.
In the previous week, Adial Pharmaceuticals had 5 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 6 mentions for Adial Pharmaceuticals and 1 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.42 beat Adial Pharmaceuticals' score of -0.50 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.
Adial Pharmaceuticals has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Adial Pharmaceuticals' return on equity of -128.67% beat Cadrenal Therapeutics' return on equity.
Summary
Adial Pharmaceuticals and Cadrenal Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Cadrenal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cadrenal Therapeutics Competitors List
Related Companies and Tools
